All In Biotech

Drug Trial Radar · NCT07404137

A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without Food

A Randomized, Single Dose, Crossover Study to Assess the Effect of Food on the Pharmacokinetics of Single Dose, Orally Administered, Combined Zibotentan/Dapagliflozin in Healthy Participants

Last checked: Nov 20, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

26

Actual

Start

Feb 16, 2026

Primary completion

Apr 2, 2026

Study completion Apr 2, 2026

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Feb 11, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to investigate the concentrations of zibotentan and dapagliflozin in blood when given with and without food in healthy participants.

Conditions

  • Healthy Participants

Interventions

  • Zibotentan/Dapagliflozin FDCDrug

    Zibotentan/Dapagliflozin FDC will be administered as an oral tablet.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under concentration-time curve from time 0 to infinity (AUCinf)Time frame: At predefined intervals from Day 1 to Day 4 for both treatment periods
  2. Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast)Time frame: At predefined intervals from Day 1 to Day 4 for both treatment periods
  3. Maximum observed drug concentration (Cmax)Time frame: At predefined intervals from Day 1 to Day 4 for both treatment periods

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Glendale, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.